Yang Luo
Chongqing University of Posts and Telecommunications(CN)Zhejiang Chinese Medical University(CN)Southwest University(CN)Sun Yat-sen University(CN)China Pharmaceutical University(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Third Affiliated Hospital of Southern Medical University(CN)Fourth People's Hospital of Sichuan Province(CN)Affiliated Hospital of North Sichuan Medical College(CN)Chinese Academy of Medical Sciences Dermatology Hospital(CN)First Affiliated Hospital of Chengdu Medical College(CN)Stomatology Hospital(CN)Hospital of Stomatology, Sun Yat-sen UniversitySouthern Medical University(CN)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Breast Lesions and Carcinomas
Most-Cited Works
- → Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer(2017)231 cited
- → Loss-of-function mutations of an inhibitory upstream ORF in the human hairless transcript cause Marie Unna hereditary hypotrichosis(2009)212 cited
- → In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China(2022)118 cited
- → The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first‐line chemotherapy of HER2‐negative metastatic breast cancer(2019)114 cited
- → RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.(2021)102 cited